CEO COMMENTS
Nicholas Waters comments the third quarter 2021
For the third quarter of 2021 IRLAB has shown a positive result of SEK 120m, primarily due to the licensing of our drug candidate mesdopetam to Ipsen, a global pharmaceutical firm. The mesdopetam deal is transformational for IRLAB – we have shown that our business model works and that our ISP research platform is an effective tool for developing drug candidates that are attractive to the market.
LATEST REPORTS
Q2
Delårsrapport >
CEO comments >
Presentation >
Q3 Webcast >
2020
Årsrapport >
CEO comments >
Presentation >
2020 Webcast >
IRLAB’s drug candidate mesdopetam’s Phase I results published in scientific journal PR&P
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a scientific paper reporting the clinical phase I study results for drug candidate mesdopetam has been published in the journal Pharmacology Research & Perspectives (PR&P). Mesdopetam is a dopamine D3 receptor antagonist and is currently being evaluated in an international Phase IIb/III study for the treatment of levodopa-induced dyskinesias (LIDs) in Parkinson’s disease.
Read More >FINANCIAL CALENDAR
NEXT
FEBRUARY 23, 2022
Year end report
FOLLOWING
APRIL 4-8, 2022
Annual report
MAY 11, 2022